Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and preven...
Enregistré dans:
Auteurs principaux: | Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Molnupiravir; an effective drug in treating COVID-19?
par: Alireza Pouramini, et autres
Publié: (2022) -
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
par: Maria L. Agostini, et autres
Publié: (2018) -
Antiviral research
Publié: (1981) -
A Novel Intronic Circular RNA Antagonizes Influenza Virus by Absorbing a microRNA That Degrades CREBBP and Accelerating IFN-β Production
par: Zhiyuan Qu, et autres
Publié: (2021) -
Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
par: Jeremy C. Jones, et autres
Publié: (2018)